Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRNA

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Moderna Stock: Analyst Estimates & Ratings

Moderna Stock: Analyst Estimates & Ratings

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

What to Expect From Moderna's Q1 2025 Earnings Report

Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

MarketBeat Week in Review – 03/10 - 03/14

Stocks continued to be under pressure on concerns over tariffs and growing inflation concerns, but history shows that corrections can set up opportunities

Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

inkl

Read news from The Economist, FT, and more,
with one subscription

Moderna: A Generational Opportunity for Investors in 2025

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

Do Wall Street Analysts Like Moderna Stock?

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

Here's What to Expect From Moderna's Next Earnings Report

Here's What to Expect From Moderna's Next Earnings Report

Moderna is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a significant triple-digit profit dip.

After a Reset Year, Is Moderna Stock Poised for a Comeback?

After a Reset Year, Is Moderna Stock Poised for a Comeback?

Moderna had a rough 2024 and is starting 2025 with lowered forecasts, but is focused on getting 10 FDA approvals in the next three years. Is now time to buy?

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna Stock Plummets 16% After £819.59M Guidance Cut Over Respiratory Vaccine Flop

Moderna is expediting its cost-cutting program and rolling back R&D amid a drop in vaccination rates and low revenues from a new vaccine.

International Business Times UK

Moderna Stock Is Volatile Amid Bird Flu Developments

Moderna Stock Is Volatile Amid Bird Flu Developments

Moderna stock has been volatile this week as the first death in the U.S. connected to bird flu was reported. Here's what you need to know.

What Were the 4 Worst-Performing Stocks in the S&P 500 in 2024?

What Were the 4 Worst-Performing Stocks in the S&P 500 in 2024?

As 2025 starts to unfold, let's take a look back at the four worst-performing stocks in the S&P 500 from last year.

Get all your
news in one place.

100's of premium titles.
One news app.

Moderna Shares Spike on H5N1 News—What’s Next for Investors?

MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025

Stock Market Today: Stocks Are Mixed Ahead of the Fed

Two of the three main equity indexes closed higher on the first day of the final Fed Week of 2024.

Is Moderna Stock Underperforming the Dow?

Moderna has significantly underperformed the Dow over the past year, and analysts are cautious about the stock’s prospects.

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Get all your
news in one place.

100's of premium titles.
One news app.

Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Stocks Extend Post-Election Gains Ahead of the FOMC Meeting

The S&P 500 Index ($SPX ) (SPY ) today is up +0.36%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.84%. Stocks today are moderately higher, with the S&P 500, the Dow Jones Industrials, and...

Earnings Preview: What to Expect From Moderna's Report

Moderna is all set to release its fiscal third-quarter earnings next month, and analysts project its loss to rise in double digits.

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Is Moderna Stock Underperforming the Nasdaq?

While Moderna has underperformed the broader Nasdaq index in 2024, analysts are reasonably bullish about the stock's potential.

Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?

Moderna has underperformed many of its peers and the broader market YTD, but Wall Street analysts are optimistic about the stock’s prospects.

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to release its fiscal second-quarter earnings next month, and analysts project a narrower loss.

1 2 3 4 5

People

206,837 stories

Robert F. Kennedy Jr

Gabriel OsorioMazilli

Stephane Bancel

Stéphane Bancel

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

405,698 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play